Company intelligence / Profile preview
Arrivo BioVentures
Morrisville, North Carolina, United Statesarrivobio.com ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Other
01
Overview
Positive results from qEEG and BNA Study of SP-624 on Neural Brain Activity Related to Depression and Cognition announced in January 2025. SP-624 has begun Phase 1 study as the first potential treatment specifically for women with Major Depressive Disorder[6].
- Therapeutic areas
- PsychiatryGastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Mayo ClinicDaiichi Sankyo
Beyond the preview
Go deeper on Arrivo BioVentures.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arrivo BioVentures.